Related Experiment Video

Updated: Apr 16, 2026

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.5K

Inhibition of the JAK2/STAT3 signaling pathway exerts a therapeutic effect on osteosarcoma

Jun Yan1, Qianliang Wang1, Kang Zou1

  • 1Department of Orthopedics, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China.

Molecular Medicine Reports
|March 12, 2015
PubMed

Insights

Targeting the JAK2/STAT3 pathway with FLLL32 shows promise for treating osteosarcoma (OS). This specific inhibitor effectively reduced OS cell growth and tumor progression in preclinical models, suggesting a new therapeutic avenue.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Osteosarcoma (OS) is a prevalent malignant bone tumor with poor survival rates despite current treatments.
  • The signal transducer and activator of transcription 3 (STAT3) pathway is recognized as an oncogene and potential therapeutic target in various cancers.
  • There is an unmet need for novel therapeutic strategies to improve outcomes for high-grade OS patients.

Purpose of the Study:

  • To investigate the potential of inhibiting the janus kinase 2 (JAK2)/STAT3 pathway as a therapeutic strategy for osteosarcoma.
  • To evaluate the efficacy of FLLL32, a specific JAK2/STAT3 inhibitor, in preclinical models of OS.

Main Methods:

  • In vitro assessment of FLLL32's effect on OS cell growth.
  • In vivo evaluation of FLLL32's efficacy in an OS xenograft nude mouse model.
  • STAT3 knockdown using short hairpin RNA (shRNA) to assess its role in OS formation in vivo.

Main Results:

  • FLLL32 demonstrated significant inhibition of OS cell growth in vitro.
  • FLLL32 treatment delayed tumor growth in the OS xenograft nude mouse model.
  • STAT3 knockdown via shRNA also delayed OS formation in vivo, confirming the pathway's importance.

Conclusions:

  • The JAK2/STAT3 pathway plays a critical role in osteosarcoma development and progression.
  • Pharmacological inhibition of JAK2/STAT3 using FLLL32 presents a promising therapeutic strategy for osteosarcoma.
  • Targeting the JAK2/STAT3 pathway offers a potential new treatment approach for patients with osteosarcoma.

More Related Videos

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.4K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.8K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K